Allogeneic CD34+ Selected Hematopoietic Stem Cell Boost Following CAR
T-cell Therapy in a Patient with Prolonged Cytopenia and Active
Infection
Abstract
Hematological toxicity (hematotoxicity) is the most common long-term
adverse effect following the use of CD19-chimeric antigen receptor
(CD19-CAR) T-cell therapies. However, its management remains unclear. We
present the case of a 21-year-old who received CD19-CAR T-cell therapy
for relapse following a haploidentical transplant. He developed
hematotoxicity and consequently multiple life-threatening infections. We
administered a CD34+ hematopoietic stem cell boost (HSCB) from his
transplant donor that led to hematopoietic recovery and resolution of
his infections without any effect on the activity of CD19-CAR T cells.
CD34+ HSCB can be a safe and effective option to treat hematotoxicity
following CD19-CAR T-cell therapy.
, 
